Practice
Featured experience
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
Vinci Partners $100 million placement and strategic partnership with Ares
We advised Vinci Partners on the private placement
UCT acquisition of HIS Innovations Group
We advised UCT on the acquisition
Orbital Infrastructure DIP financing and section 363 purchase of Front Line Power
We advised the prepetition secured lenders and DIP lenders
Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant
We are advising Roche on the acquisition
Ferrara Candy acquisition of Jelly Belly Candy
We are advising Ferrara on the acquisition
Party City emerges from chapter 11
We advised an ad hoc group of first-lien noteholders in connection with Party City’s chapter 11 proceedings
Genetron $126 million going-private transaction
We are separately advising Genetron and the special committee of its board on the transaction
MSCI acquisition of Trove Research
We are advising MSCI on the acquisition
ExxonMobil $59.5 billion acquisition of Pioneer Natural Resources
We are advising ExxonMobil on the transaction